Vendor Intelligence Report: Top Peptide

Executive summary

Across 38 Finnrick lab tests, Top Peptide shows 32 pass / 6 fail — an 84% overall pass rate. The headline is pass-dominant, but uneven. Retatrutide and GHK-Cu carry the strongest current signal, tirzepatide is visibly weaker, and BPC-157 is where the data points buyers toward another source. Ratings also move under stricter purity-and-fill assumptions.

The identity story is more complicated than the storefront. topxpeptide.com is recent, while the surrounding YH/YiHang footprint appears earlier: an operator email domain separate from the storefront, a public Janoshik COA using the YH Peptide name, and social/forum artifacts tie the buyer-facing brand to a broader Xi'an sales identity. The report separates high-confidence operating links from unproven same-owner assumptions.

Corporate and operational records add friction. A current Xi'an Yihang registry candidate, an older dissolved Yihang record, changing Xi'an addresses, rotating Hong Kong phone numbers, and no clearly disclosed contracting entity make accountability harder than the website's production and GMP language suggests. The site also exposed a ThinkPHP stack trace and server path, and the investigation found only one public COA with no catalog-wide sterility, endotoxin, heavy-metals, or batch-library support.

For buyers already considering Top Peptide, this is a product-specific and identity-specific read: stronger on current retatrutide/GHK-Cu evidence, weakest on BPC-157, and cautious on tirzepatide or any YH/YiHang-linked, batchless inventory because alias-linked Finnrick captures show identity, fill-accuracy, and traceability failure modes.

Inside the full report:

• Current Top Peptide pass/fail record, methodology-divergence chart, trajectory grid, and Appendix A laboratory data
• Alias-linked Finnrick captures under Xian Yihang Technology showing identity, fill-accuracy, and missing-batch-ID failure modes
• YH/YiHang operating-identity evidence from xayhang.com, a public Janoshik COA, Facebook, Reddit, and forum records
• Corporate filings and address trail covering the active 2024 Xi'an entity, an older dissolved record, and related Yihang-name leads
• Website infrastructure review including Alibaba Cloud hosting, ThinkPHP debug exposure, contact rotation, and payment-visibility limits
• Brand-confusion and regulatory analysis covering unrelated lookalike domains, the CBP Cincinnati action, and the Health Canada warning

Risk assessment

• BPC-157 quality-consistency risk — high: Current Finnrick record is split 2 pass / 2 fail across 4 tests with a 49.39% rating; buyers should prefer a stronger-testing BPC-157 source.
• Alias-linked GHK-Cu and tesamorelin incident-history risk — high: High-confidence YH/YiHang alias records captured GHK-Cu identity/fill failures and tesamorelin underfill concerns; demand batch-specific verification for any YH-linked inventory.
• Tirzepatide quality-consistency risk — medium: Current Top Peptide tirzepatide is pass-dominant but weaker than retatrutide and GHK-Cu: 18 tests, 14 pass / 4 fail, 79.02% Finnrick rating.
• Documentation and GMP-verification risk — high: Only one public COA was found; no public GMP certificate, sterility, endotoxin, heavy-metals, batch-COA library, or anti-counterfeit verification system was verified.
• Corporate accountability and address-instability risk — medium: Records show a recent Xi'an Yihang entity with ¥50,000 registered capital, a dissolved name predecessor, and multiple inconsistent Xi'an addresses.
• Brand-confusion and copycat-domain risk — medium: Similar YH/Top Peptide domains were found to be unrelated, while Top Peptide does not publish an authoritative official-channel or authorized-reseller list.
• Website security and buyer-data risk — medium: The production ThinkPHP site exposed stack traces and server paths, and sales/payment handling is not presented through a transparent checkout or dispute process.
• Customs seizure and regulatory risk for Western buyers — high: CBP and Health Canada actions are not vendor-specific but target the same China-origin unauthorized injectable peptide channel and products overlapping Top Peptide's catalog.